Document is current
Any future updates will be listed below
-
Authors
Ruddy, Terrence D.
Al-Mallah, Mouaz
Arrighi, James A.
Bois, John P.
Bluemke, David A.
Di Carli, Marcelo F.
Dilsizian, Vasken
Gropler, Robert J.
Jadvar, Hossein
Malhotra, Saurabh
Pelletier-Galarneau, Matthieu
Schindler, Thomas H.
Woodard, Pamela K.
Chareonthaitawee, Panithaya http://orcid.org/0000-0002-3811-8712
- License Information
-
More Information
Article History
Received: 12 April 2022
Accepted: 27 April 2022
First Online: 19 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: Terrence D. Ruddy: GEHealthcare-Research Grant. Mouaz Al-Mallah: Research support: Siemens; Consultant: Pfizer, Jubulant, Philips. James A. Arrighi, John P. Bois, David A. Bluemke, Vasken Dilsizian: Nothing to disclose. Marcelo F. Di Carli: Institutional Research Grant: Gilead Sciences. Robert J. Gropler: GE-Healthcare and Medtrace—Research grants; AHA-editor stipend. Hossein Jadvar: Radiomedix-Advisory Board; Lantheus-Speaker’s Bureau; Blue Earth Diagnostics-Consultant; Bayer-Consultant. Saurabh Malhotra: Speakers Bureau—Pfizer Inc, and Alnylam; Advisory Board—Alnylam and BridgeBio. Matthieu Pelletier-Galarneau: Jubilant Radiopharma-Consulting, Research Funds. M.P.-G. is supported by a Junior 1 Research Award from the Fonds de Recherche du Québec—Santé (FRQS). Thomas H. Schindler: GE: multicenter Flupiridaz cardiac PET study. Pamela K. Woodard: None related to this article. Other research funding: NIH, Siemens, Bayer. Panithaya Chareonthaitawee: BioClinica-Consulting; UptoDate—Royalties.
